CareLit · DOI-Nachweis · Klinische Pädiatrie
Analysis of mutations in the BCR-ABL TK domain in CML patients
DOI 10.1055/s-0030-1254459
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Neßlboeck, S Preuner, T Lion
ZeitschriftKlinische Pädiatrie
Ausgabe05/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: The tyrosine kinase (TK) inhibitor imatinib (Gleevec®) directed against the BCR-ABL TK domain has become the standard of treatment in patients with chronic myeloid leukemia (CML). Despite its effectiveness in CML treatment, primary refractory disease or secondary resistance remains a problem. The mechanisms underlying resistance is most commonly associated with point mutations within the ABL TK domain. M…
Zitieren
Zitierempfehlung
M Neßlboeck, S Preuner, T Lion (2010) Analysis of mutations in the BCR-ABL TK domain in CML patients. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0030-1254459
Mit CareLit weiterarbeiten